The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Target proteins or DNA sequences are immobilized to the wells of a microtiter plate. Many genetic sequences are expressed in a bacteriophage library in the form of fusions with the bacteriophage coat protein, so that they are displayed on the surface of the viral particle. The protein displayed corresponds to the genetic sequence within the phage. This phage-display library is added to the dish and after allowing the phage time to bind, the dish is washed. Phage-displaying proteins that interact with the target molecules remain attached to the dish, while all others are washed away. Attached phage may be eluted and used to create more phage by infection of suitable bacterial hosts. The new phage constitutes an enriched mixture, containing considerably less irrelevant phage (i.e. non-binding) than were present in the initial mixture. Steps 3 to 5 are optionally repeated one or more times, further enriching the phage library in binding proteins. Following further bacterial-based amplification, the DNA within the interacting phage is sequenced to identify the interacting proteins or protein fragments.
Ion exchange is a reversible interchange of one species of ion present in an insoluble solid with another of like charge present in a solution surrounding the solid. Ion exchange is used in softening or demineralizing of water, purification of chemicals, and separation of substances. Ion exchange usually describes a process of purification of aqueous solutions using solid polymeric ion-exchange resin. More precisely, the term encompasses a large variety of processes where ions are exchanged between two electrolytes. Aside from its use to purify drinking water, the technique is widely applied for purification and separation of a variety of industrially and medicinally important chemicals. Although the term usually refers to applications of synthetic (human-made) resins, it can include many other materials such as soil. Typical ion exchangers are ion-exchange resins (functionalized porous or gel polymer), zeolites, montmorillonite, clay, and soil humus. Ion exchangers are either cation exchangers, which exchange positively charged ions (cations), or anion exchangers, which exchange negatively charged ions (anions). There are also amphoteric exchangers that are able to exchange both cations and anions simultaneously. However, the simultaneous exchange of cations and anions is often performed in mixed beds, which contain a mixture of anion- and cation-exchange resins, or passing the solution through several different ion-exchange materials.
Deputy Director of Adult Social Care, Care Quality Commission. For services to Adult Social Care. Dr. Meenakshi Nagpaul (Meena Thakur). General Practitioner, Honeypot Medical Centre and Clinical Director, Harrow East Primary Care Network. For services to the NHS. Jacqueline Neilson. Chief Executive Officer, Rain Rescue. For services to Animal Welfare. William Lambton Nicholson. Leader, Newbury Working Party Group. For services to Canal Restoration. June Edna Nicol-Dundas. Foster Carer, Fostering London. For services to Young People. Christopher Mansfeldt Norman. Chief Executive and Founder, GOOD Agency. For services to the Business and Charitable Sectors. John Norris. Chair, B&M Longworth (Edgworth) Ltd. For services to Innovation, to Sustainability and to International Trade. Lawrence John O'Halleron. Chair, Big Local Gateshead. For services to the community in Gateshead, Tyne and Wear. Leona O'Neil. Founder, The Boom Foundation. For services to Charitable Fundraising for People with Sarcoma. Harry Clive O'Neill. For charitable services to the community in County Down. Lanré Charles Olagoke. Founder, Art-Alive Arts Trust. For services to Charity and to Young People. David Edward Olney. Assistant Head Ukraine, Security Policy and Operations, Ministry of Defence. For services to Defence. Tori Pamela Anne Olphin. Chief Data Scientist and Head of Research, Thames Valley Police. For services to Technology in the Public Sector. Ehinor Otaigbe-Amedu. For services to Women in Greater Manchester. Lydia Jean Otter.
Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study. However, PSPs hold large potential for translating degradomics into clinical applications, as once a PSP is established it could aid in quantifying proteolytic signature biomarkers in Single Reaction Monitoring (SRM) and Multiple Reaction Monitoring (MRM) type clinical assays.
Sources: en.wikipedia.org
An outbreak of avian botulism leads to the deaths of about 1,000 birds at the Waikouaiti wastewater treatment plant near Dunedin and the Washdyke Lagoon near Timaru. 27 January – New Zealand Foreign Minister Winston Peters' suspends New Zealand's aid programme to Kiribati after Kiribati President Taneti Maamau cancelled three pre-arranged meetings including one scheduled for mid January 2025. The New Zealand Government had wanted to discuss how NZ$102 million worth of aid money allocated to Kiribati between 2021 and 2024 was being spent. 29 January: Prime Minister Luxon and Transport Minister Chris Bishop announces plans by the Government to reverse blanket speed limits on 38 sections of the New Zealand state highway network and seek public consultation on raising the speed limits for another 49 state highway sections. Advocacy group Toitū te Tiriti files an urgent Waitangi Tribunal claim against proposed Regulatory Standards Bill, claiming it would undermine the Treaty of Waitangi. 30 January: Mount Taranaki is officially recognised as a person under the name Taranaki Maunga. The $130 million Queenstown Town Centre arterial road opens. 31 January: Health Minister Simeon Brown confirms that a new Dunedin Hospital will be built on the site of the former Cadbury factory at a cost of NZ$1.9 billion. A power outage affects 22,000 Transpower customers in Rotorua. The Royal New Zealand Air Force formally retires its fleet of five C-130H Hercules planes.
In 1999, Yates’ group [11] loaded strong-cation exchange (SCX) and reversed phase liquid chromatography (RPLC) stationary phases sequentially into a capillary column coupled with tandem mass spectrometry (MS/MS) in the analysis of peptides, which became one of the most efficient technique in proteomics afterwards.
==== Austria ==== The highest radon concentrations in Austria were measured in 1991 in the municipality of Umhausen in Tyrol. Umhausen has about 2300 inhabitants and is located in the Ötztal valley. Some of the houses there were built on a bedrock of granite gneiss. From this porous subsoil, the radon present in the rock seeped freely into the unsealed cellars, which were contaminated with up to 60,000 Becquerels of radon per cubic meter of air. Radon levels in the apartments in Umhausen have been systematically monitored since 1992. Since then, extensive radon mitigation measures have been implemented in the buildings: New buildings, sealing of cellar floors, forced ventilation of cellars or relocation. Queries in the Austrian Health Information System (ÖGIS) have shown that the incidence of new cases of lung cancer has declined sharply since then. The Austrian National Radon Project (ÖNRAP) has studied radon exposure throughout the country. Austria also has a Radiation Protection Act as a legal basis. Indoor limits were set in 2008 The Austrian Ministry of the Environment states that
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.